Pazopanib (GW786034), by GlaxoSmithKline, is a second-generation multi-targeted tyrosine kinase inhibitor against all VEGF receptors (VEGFR-1, VEGFR-2, VEGFR-3) PDGFR-a, PDGFRβ, and c-kit that blocks tumour growth & inhibits angiogenesis.

An early phase trial is evaluating the safety, and pharmacokinetics of Pazopanib eye drops in patients with neovascular AMD⁽²⁷⁾.